Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Aug 17;14(1):19082.
doi: 10.1038/s41598-024-70410-w.

Methylxanthine use in infants with hypoxic-ischemic encephalopathy: a retrospective cohort study

Madeleine E Laughon #  1 , Jacob K Johnson #  1 , Rachel G Greenberg  2 , Reese H Clark  3 , Wesley M Jackson  4
Affiliations
Multicenter Study

Methylxanthine use in infants with hypoxic-ischemic encephalopathy: a retrospective cohort study

Madeleine E Laughon et al. Sci Rep. .

Abstract

Therapeutic hypothermia is the standard treatment for hypoxic-ischemic encephalopathy (HIE), but despite its widespread use, the rates of mortality and neurodevelopmental impairment for moderate to severe HIE remain around 30%. Methylxanthines, such as caffeine and aminophylline, have potential neuroprotective effects in the setting of hypoxic-ischemic injury. However, data on the safety and efficacy of methylxanthines in the setting of therapeutic hypothermia for HIE are limited. This retrospective multicenter study examined in-hospital outcomes in 52 infants with HIE receiving methylxanthines and therapeutic hypothermia. The frequency of mortality and in-hospital morbidities were similar to those of infants enrolled in clinical trials undergoing therapeutic hypothermia without adjunctive therapies. Clinical trials of methylxanthines for neuroprotection in HIE are needed to determine safety and efficacy and should explore optimal dosing and timing of methylxanthine administration.

PubMed Disclaimer

Conflict of interest statement

MEL, JKJ, RHC, and WMJ have no conflicts of interest to disclose. RGG has received support from industry for research services (https://dcri.org/about-us/conflict-of-interest/).

References

    1. Shankaran, S. et al. Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: A randomized clinical trial. JAMA318(1), 57–67 (2017). 10.1001/jama.2017.7218 - DOI - PMC - PubMed
    1. Bruschettini, M., Moreira, A., Pizarro, A. B., Mustafa, S. & Romantsik, O. The effects of caffeine following hypoxic-ischemic encephalopathy: A systematic review of animal studies. Brain Res.1790, 147990 (2022). 10.1016/j.brainres.2022.147990 - DOI - PubMed
    1. Sabir, H. et al. Comparing the efficacy in reducing brain injury of different neuroprotective agents following neonatal hypoxia-ischemia in newborn rats: A multi-drug randomized controlled screening trial. Sci. Rep.13(1), 9467 (2023). 10.1038/s41598-023-36653-9 - DOI - PMC - PubMed
    1. Kilicdag, H., Daglioglu, Y. K., Erdogan, S. & Zorludemir, S. Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury. J. Matern. Fetal Neonatal Med.27(14), 1470–1475 (2014). 10.3109/14767058.2013.878694 - DOI - PubMed
    1. Di Martino, E. et al. Defining a time window for neuroprotection and glia modulation by caffeine after neonatal hypoxia-ischaemia. Mol. Neurobiol.57(5), 2194–2205 (2020). 10.1007/s12035-020-01867-9 - DOI - PMC - PubMed

Publication types

LinkOut - more resources